Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's up $LGBI ?? :)
Nice O/S !! :) $LGBI
Outstanding Shares 648,118,117 04/11/2022
Authorized Shares 3,500,000,000 04/11/2022
https://www.otcmarkets.com/stock/LGBI/security
Nice to see anything! $LGBI !!!
$HIRU ..sounds like a GREAT time to buy!! :)
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
April 13 2022 - 05:45AM
InvestorsHub NewsWire
Alert
Print
Share On Facebook
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
San Francisco, CA -- April 13, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its licensed dactinomycin nanoemulsion. The successful completion of the feasibility stage marks the initial planned milestone for this development project. Data is currently under evaluation and discussions regarding future development and milestones are underway.
The goal of this initial feasibility phase was to demonstrate the capability of producing viable drug formulations with desirable delivery system characteristics. These include the encapsulation of the active pharmaceutical ingredient (dactinomycin) by the nanoemulsion, a controlled release over time, desirable storage stability, and appropriate particle size and surface charge.
While many nanoemulsion formulations are limited by very short storage stability, some with shelf-lives of mere hours after formulating the dosing solution. Early feasibility data collected from the licensed proprietary nanoemulsion formulation being developed as part of this project has demonstrated multiple weeks of stability, with anticipated stability of several months. In addition, initial analytical method validation work was conducted at an independent contract laboratory to develop the capability of assessing drug concentration in samples, which will be critical for successful completion of future preclinical studies.
From the various formulations created and assessed during this feasibility phase, two likely drug formulations have been identified that have the desired characteristics to enable further development.
The nanoemulsion delivery system is intended to increase the overall safety of dactinomycin, a potent cancer drug that has been previously cleared to treat cancer, including pediatric cancer, but has limited utility due to its high toxicity and narrow safety margin ("therapeutic window"). By encapsulating the dactinomycin in a nanoemulsion carrier, the drug is released over time and thus improves its safety profile (much like coated aspirin is designed to prevent stomach upset without interfering with its pain-relieving properties).
With testing that has been completed, Oncology Pharma has growing confidence that this method of delivery will allow for improved safety of delivering dactinomycin to treat cancer. Additional data and information from the testing will be released as it becomes available.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.
https://ih.advfn.com/stock-market/USOTC/oncology-pharma-pk-ONPH/stock-news/87824518/oncology-pharma-completes-feasibility-phase-of-its
$TLSS !!! :) :) :)
$NTRR blast from the past!! :) http://videmoji.com/ntrr/images/SYD-JIM-MUGSHOT-LMAO-VIVIS.jpg
http://videmoji.com/ntrr/images/Vivis-1.jpg
http://videmoji.com/ntrr/images/Vivis-2.jpg
http://videmoji.com/ntrr/images/Vivis-3.jpg
http://videmoji.com/ntrr/images/Vivis-4.jpg
http://videmoji.com/ntrr/images/Vivis-5.jpg
http://videmoji.com/ntrr/images/Vivis-6.jpg
http://videmoji.com/ntrr/images/Vivis-7.jpg
http://videmoji.com/ntrr/images/Vivis-8.jpg
http://videmoji.com/ntrr/images/Vivis-9.jpg
http://videmoji.com/ntrr/images/Vivis-10.jpg
http://videmoji.com/ntrr/images/Vivis-11.jpg
$GNCP !!!! :)
ok... please send info? so we can see for ourselves???? :)
NOT everything of mine, finally!! $AMLM
.0101 CLOSE !!! :) $RGBP !!! 164.44MM shares traded!!!
.0105 HOD !!! :) $RGBP !!!
.0099 HOD !!! :) $RGBP !!!
.0094 HOD !!! :) $RGBP !!!
.0093 HOD !!! :) $RGBP !!!
.0089 HOD !!! :) $RGBP !!!
.0088 HOD !!! :) $RGBP !!!
$RGBPP !!! :)
.0086 HOD !!! :) $RGBP !!!
:) $GSTC !!! :)
.0085 HOD !!! :) $RGBP !!!
.0084 HOD !!! :) $RGBP !!!
.0081 HOD !!! :) $RGBP !!!
Hey you! :)
$AMLM !! :)
$PDIV may have some more to it, behind the scenes! :)
Seems much more activity! :) $PDIV
Let's keep rolling!! $PDIV !
$GGII !!! :)
Premier's holdings in GNCC exceed 55% of GNCC's shares of outstanding Voting Common Stock.
PREMIER DEVELOPMENT & INVESTMENT, INC. UPDATE - INCREASE IN HOLDINGS IN GNCC CAPITAL, INC.
$GNCP
PR Newswire
LAS VEGAS, Dec. 21, 2021
We can now confirm that Premier's holdings in GNCC exceed 55% of GNCC's shares of outstanding Voting Common Stock.
https://www.otcmarkets.com/stock/PDIV/news/PREMIER-DEVELOPMENT--INVESTMENT-INC-UPDATE---INCREASE-IN-HOLDINGS-IN-GNCC-CAPITAL-INC?id=336657
$GNCP
Premier's holdings in GNCC exceed 55% of GNCC's shares of outstanding Voting Common Stock.
PREMIER DEVELOPMENT & INVESTMENT, INC. UPDATE - INCREASE IN HOLDINGS IN GNCC CAPITAL, INC.
PR Newswire
LAS VEGAS, Dec. 21, 2021
We can now confirm that Premier's holdings in GNCC exceed 55% of GNCC's shares of outstanding Voting Common Stock.
https://www.otcmarkets.com/stock/PDIV/news/PREMIER-DEVELOPMENT--INVESTMENT-INC-UPDATE---INCREASE-IN-HOLDINGS-IN-GNCC-CAPITAL-INC?id=336657
mine is .0194 !! :) $TLSS !!! :)
$RGBP !!! :)
$TLSS Blessed happy Saturday/Sunday to all!!!!!!! :)
$RGBP blessed happy Saturday/Sunday to all!!!!!!! :)
:) $TLSS !!! :)
Amen!!! :) $GNCP !!!